Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Peter Thiel
Biotech
Anti-aging biotech NewLimit nabs $435M to rejuvenate old cells
Backed by Peter Thiel's Founders Fund, NewLimit looks to push a liver-targeting mRNA therapeutic into the clinic next year.
Darren Incorvaia
Jun 2, 2026 1:00pm
Neuralink nabs $280M after scoring FDA trial nod
Aug 8, 2023 12:32pm
John Mascola moves on from NIAID's R&D hub—Chutes and Ladders
Apr 1, 2022 9:30am
Palantir snags IBM Watson Health vet to be first CMO
May 3, 2021 7:00am
Alloy Therapeutics nabs a $75M series C
Apr 2, 2021 8:55am
The money keeps coming for Eli Lilly COVID-19 partner AbCellera
May 27, 2020 7:45am
